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Abstract 
An acquired loss of renal DNaseI has recently been shown to promote transformation of mild 
mesangial lupus nephritis into membrano-proliferative end-stage organ disease. In this study, 
we analyzed expression profiles of DNaseI in other organs of lupus-prone (NZBxNZW)F1 
mice during disease progression to determine if silencing of the renal DNaseI gene is an organ 
specific feature or if loss of DNaseI reflects a systemic error in mice with sever lupus 
nephritis. Our results demonstrate normal or elevated levels of DNaseI mRNA and enzyme 
activity in liver, spleen and serum samples of (NZBxNZW)F1 mice throughout all stages of 
lupus nephritis. DNaseI activity was dramatically reduced only in kidneys of mice with sever 
nephritis and was the only nuclease that was down-regulated, while 6 other nucleases 
(DNaseIl1-3, caspase activated deoxyribonuclease, Dnase2a, and endonuclease G) were 
largely normally expressed in kidneys, liver and spleen. Loss of renal DNaseI was not 
accompanied by changes in serum DNaseI activity, suggesting an independent mechanism of 
DNaseI regulation in circulation and in kidneys, and an absence of compensatory up-
regulation of serum DNaseI activity in case of renal DNaseI deficiency. Thus, silencing of 
renal DNaseI is a unique renal feature in membrano-proliferative lupus nephritis. 
Determination of mechanism(s) responsible for DNaseI down-regulation is a future step in 




Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by 
production of a variety of autoantibodies to nuclear antigens.1 Formation and sequential 
deposition of immune complexes in visceral organs represent a basic pathogenic mechanism 
of the disease.2 The potentially most severe clinical manifestation of SLE is lupus nephritis.3 
It is initiated through immune complex deposition in glomeruli which impose kidney 
dysfunction and finally renal failure.4,5 However, progression of the disease varies in 
intensity. Some patients experience progression from the mild mesangial form into full-blown 
membrano-proliferative nephritis, while others remain with a benign mesangial pattern 
throughout life.6,7  
In a recent study, we observed that lupus nephritis in female (NZBxNZW)F1 (BW)  
mice is a principally two-stepped organ disease.8 The early phase correlated with deposition 
of complexes of chromatin fragments and IgG in the mesangial matrix. Progression of the 
disease, which was characterized by deposition of large chromatin fragments in glomerular 
basement membranes (GBM) and severe proteinuria, correlated with an acquired loss of renal 
DNaseI mRNA level and enzyme activity. Loss of DNaseI, as a dominant renal nuclease,9 
correlated with reduced chromatin degradation during regular apoptosis in kidneys.10,11 In a 
case of impaired clearance of apoptotic cells,12 this may explain increased exposure of 
chromatin fragments in membranes and matrices of affected glomeruli. Binding of such 
fragments to GBM are most probably facilitated by increased matrix metalloprotease 2 
(MMP2) and MMP9 expression, observed in nephritic kidneys.13 
Expression profiles of DNaseI in other organs in BW mice during kidney disease 
progression are unknown. In sera, DNaseI was shown to be reduced in mice with lupus 
nephritis.14,15 The reason for this is, however, unclear. Either, DNaseI is down-regulated in 
organs responsible for secreted DNaseI, or serum DNaseI is reduced just because of 
 3
consumption during nephritis. Therefore, it became important to verify if silencing of the 
renal DNaseI gene is an organ specific feature or if it reflects a systemic error in BW mice 
with sever lupus nephritis.  
The aim of the present study was, therefore, to determine i. whether loss of renal 
DNaseI is unique to the kidney, or occurs simultaneously in other organs as well, ii. whether 
silencing of renal DNaseI is a selective process not involving other nucleases in defined 
stages of the disease; and iii. whether there is any compensatory up-regulation of DNaseI or 
other nucleases in kidneys and other organs. 
In this study we examined DNaseI expression in kidneys, livers and spleens of BW 
mice at different stages of lupus nephritis. This allowed us to analyze for deviations in 
DNaseI levels in one organ with strongly (liver) and another organ with marginally detectable 
DNaseI (spleen). Published data have demonstrated that liver is the main source for serum 
DNaseI16 while in spleen, the level of the DNaseI is very low in a physiological context.17,18 
Both organs are also responsible for clearance of circulating immune-complexes (IC)19,20 and 
participate in the pathogenesis of lupus nephritis in a case of defective chromatin degradation. 
Therefore, data described in this study are important to inform whether the processes 
observed in the kidney are unique for DNaseI and for the kidney, or represent systemic errors 
globally in the body.   
Our results demonstrate that renal DNaseI is reduced strictly in membrano-
proliferative (end-stage) nephritis, and is the only nuclease that is down-regulated among 7 
analyzed nucleases (DNaseI, DNaseIl1-3, caspase activated deoxyribonuclease (CAD), 
Dnase2a, and endonuclease G (EndoG)). While dramatically reduced in the kidneys, DNaseI 
is not reduced in the spleen or in the liver. We observed no significant down- or up-regulation 
of any of the other 6 nucleases in the examined organs. These data and the background for 
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them may point at mechanisms responsible for silencing of the DNaseI gene as a future causal 
therapeutic target to treat and prevent progressive lupus nephritis.  
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Materials and Methods 
Animals  
Female BW and BALB/c mice were purchased from Harlan (Blackthorn, UK). Treatment and 
care of animals were in accordance with the guidelines of The Norwegian Ethical and Welfare 
Board for Research Animals, and the study was approved by the Institutional Review Board.  
 
Collection of samples from groups of mice  
Serum samples from BW mice were collected from pre-nephritic mice (Group 1, n=3), mice 
with mesangial nephritis (Group 2, n=3), and from mice with membrano-proliferative 
nephritis (Group 3, n=6). Sera were stored at –20°C. Degree of proteinuria was monitored 
weekly with sticks from Bayer Diagnostics (Bridgend, UK). Animals were euthanized by 
CO2-suffocation. Kidneys, livers and spleens were extirpated, cut, and fixed in RNAlater 
(Qiagen Nordic, Norway) for further analysis of gene transcription, or fixed in 4% buffered 
depolymerized paraformaldehyde and embedded in paraffin for immunohistochemical 
analysis, or fixed in 8% buffered depolymerized paraformaldehyde for immune electron 
microscopy (kidneys and livers only).21  The same samples were collected from sex- and age-
matched BALB/c control mice.  
 
Anti-dsDNA Enzyme-Linked Immunosorbent Assay  
Murine anti-dsDNA antibodies were detected and titrated by standard indirect ELISA, as 
described in details.22 
 
Immune Electron Microscopy  
Immune electron microscopy (IEM) was performed on murine kidney and liver sections 
exactly as described previously.21 In short, sections were incubated with rabbit anti-mouse 
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IgG (RaM IgG, Cappel, ICN Pharmaceuticals, Inc) followed by protein A conjugated with 5-
nm gold particles (PAG-5 nm, University of Utrecht, The Netherlands) to detect in vivo-
bound IgG autoantibodies. Micrographs were taken using a Jeol JEM-1010 Transmission 
Electron Microscope (Tokyo, Japan).  
 
Immunohistochemistry  
Endonucleases in kidneys and livers were detected using polink-2 plus HRP detection kit 
(Golden Bridge International, Inc, Mukilteo, WA, USA) as described in detail.10 DNaseI was 
detected by anti-DNaseI antibody (Santa Crus Biotechnology, Inc), diluted 1:50 for kidney 
and 1:30 for liver sections. CAD and EndoG were detected by anti-CAD antibody (diluted 
1:150 for kidney and 1:70 for liver) and anti-EndoG antibody (diluted 1:100 for kidney and 
1:70 for liver) from BioSite (CA, USA). Secondary antibodies and diaminobenzidine 
chromogen solution were used according to instruction provided in the kit. Sections were 




To evaluate the degree of protein expression we blindly quantified the intensity of staining in 
10 view fields per kidney and liver sections. Immunoexpression score (IEXP-SC) was adapted 
from Richardsen at. al.23 (IEXP-SC) = AEX x ISI, where AEX = percentage cellular area of 
expression and ISI = immunostaining intensity, grade 1-3. The product gives a score from 0 to 
300, which was expressed as: negative - IEXP-SC = 0; weakly positive - IEXP-SC = 1 – 100; 
moderately positive - IEXP-SC = 101 - 200; strongly positive - IEXP-SC = 201 – 300. 
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Gene Expression Analysis  
Total RNA was isolated with EZ-1 RNA tissue mini kit (Qiagen). The quality of RNA was 
analyzed by Agilent Bioanalyzer using the RNA 6000 assay kit (Agilent Technologies, Inc, 
CA). The cDNA was transcribed from 2µg of RNA using the cDNA Archive kit (Applied 
Biosystems, CA). For real time PCR we used pre-designed TaqMan Gene Expression Assays 
(Applied Biosystems, CA): Dnase1 Mm01342389_g1; Dnase1l1 Mm00510102_m1; 
Dnase1l2 Mm00481868_g1; Dnase1l3 Mm00432865_m1; CAD Mm00432822_m1; Dnase2a 
Mm00438463_m1; EndoG Mm00468248_m1; endogenous control – Mouse actin β 
4352933E, and TATA binding protein Mm00446973_m1. The assays were performed on ABI 
Prism 7900HT Sequence Detection System (Applied Biosystems). Expression levels were 
calculated using the ∆∆CT method. Data are given as fold change compared with transcription 
in 12 weeks old mice. The protocol for analysis of DNaseI expression in spleens was 
modified due to low expression levels. To be able to detect mRNAs we had to use 2 times 
higher concentration of cDNA than we used for kidney or liver samples.  
 
DNase radial diffusion assay to determine activity of neutral pH, Ca2+, and/or Mg2+ 
dependent endonucleases.  
To evaluate DNase activity in kidneys, livers, spleens and sera, a DNase radial diffusion assay 
was performed as described.24 10 mg of tissue was homogenized in DNase reaction buffer (40 
mM Tris, pH 7.6, 2 mM CaCl2 and 2 mM MgC2) with 0.1% Triton. Cell debris were removed 
by centrifugation at 13000 x g, and supernatant was stored at -80 0C. Total protein amount 
was measured using BCA assay (Pierce Biotechnology, Rockford, IL, USA). For analysis, 
tissue samples were thawed on ice, protein concentration was normalized for every tissue to 
be equal in all samples and 2.5 μl aliquots of tissues lysates were loaded into 1mm wells in a 
1% agarose gel containing 50 μg/ml calf thymus DNA (Sigma-Aldrich) (for livers and 
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spleens) or 100 μg/ml (for kidneys and sera) and 1 μg/ml ethidium bromide in DNase reaction 
buffer. Serum samples were loaded directly to the gel after defrosting on ice. Recombinant 
human DNaseI from Amersham Biosciences (Piscataway, NS, USA) was used as a standard. 
The gel was incubated in a humidified chamber at 37°C for 17 hours and photographed under 
UV illumination.  
 
Denaturing SDS-PAGE zymography (DPZ). 
DNaseI activity in the kidneys, livers and sera was determined after protein separation in a 
 10% SDS-polyacrylamide gel containing 40 μg/ml heat-denatured salmon sperm DNA 
(Invitrogen Corp, Carlsbad, CA) as described.25  
 
Native PAGE zymography (NPZ) 
In order to analyze for DNaseI in the spleens, we also performed the more sensitive native 
PAGE zymography instead of SDS-PAGE.16 DNaseI activity was determined after protein 
separation in 7.5% polyacrylamide gels containing 30 μg/ml heat-denatured salmon sperm 
DNA (Invitrogen) as described in details elsewhere.16,17  Liver samples were analyzed by 
SDS- and native PAGE zymographies, both techniques demonstrated similar results in liver 
tissue.  
 
Statistical Analysis  
One-way analysis of variance with Dunett post hoc test was used in this study. Differences 
were regarded significant at p < 0.05. 
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Results 
Analysis of serum anti-dsDNA antibodies, renal and liver morphology in BW mice. 
To investigate the DNaseI mRNA level and enzyme activity in different organs of BW mice, 
we divided female BW into 3 groups according to age, anti-DNA antibody titer and disease 
severity (Table 1). Group 1 represents young non-proteinuric, anti-dsDNA antibody negative 
BW mice. IEM analysis of corresponding kidney sections did not demonstrate any 
morphological changes (Figure 1 upper panels, Table 1). Group 2 is composed of non-
proteinuric animals with variable titers of serum anti-dsDNA antibody and deposits of 
immune complexes, seen as electron dense structures (EDS) containing IgG in the glomerular 
mesangial matrix (Figure 1 upper panels, Table 1). Nephritic BW mice with severe 
proteinuria, circulating anti-dsDNA antibodies and EDS with IgG in both the mesangial 
matrix and in GBM represent Group 3 (Figure 1 upper panels and Table 1). Liver tissue of 
animals from each group was also analyzed by IEM. We did not find any immune deposits or 
electron dense structures in liver capillary and arterial walls in any of the mice included in this 
study (Table1, Figure 1 lower panels). Sex and age matched BALB/c mice were used as 
healthy control mice. They were all negative for anti-DNA antibodies and did not have any 
immune deposits in kidneys or livers (data not shown).    
 
DNaseI expression in kidneys, livers, spleens and sera of BW mice.  
Relative DNaseI gene expression levels in different organs from Group 1-3 mice was 
analyzed by real time PCR, corresponding enzyme activity and protein expression. Figure 2 
A,B,C shows mRNA levels of DNaseI (columns) and enzyme activity (gels) in individual 
mice, as determined in kidneys (A), livers (B) and spleens (C). The average (+SD) of DNaseI 
mRNA levels in each group of mice is presented as insert for each organ. DNaseI 
zymography applied to serum samples is shown in (D).  
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DNaseI mRNA is normally expressed in pre-nephritic kidneys (Group 1, Figure 2A) 
and in kidneys from mice with mesangial nephritis (Group 2, Figure 2A). However, DNaseI 
mRNA is dramatically reduced in kidneys from Group 3 BW mice (Figure 2A). The low 
DNaseI mRNA level in Group 3 mice is also reflected by low enzyme activity as determined 
by zymography (Figure 2A) and weak protein expression in kidneys as determined by IHC 
(Figure 2E upper row). Low DNaseI expression was presented uniformly in glomeruli and 
tubuli in kidney sections from Group 3 mice.  
To analyze if silencing of the DNaseI gene in nephritic BW mice is an organ specific 
feature, mRNA levels were determined in livers and spleens of the same BW mice. Data 
demonstrate that DNaseI mRNA expression is not reduced in livers (Figure 2B) or in spleens 
(Figure 2C) in all groups of mice. Those results compare well with assays on DNaseI enzyme 
activity as analyzed by gel zymography (Figure 2B and 2C for livers and spleens, 
respectively) and IHC analysis of livers for DNaseI protein expression in situ (Figure 2E 
lower panels). DNaseI mRNA level and enzyme activity in livers in Group 2 and in spleens in 
Group 2 and 3 tended to be higher when comparing with Group 1 results. (Figure 2B and 2C, 
for livers and spleens, respectively). However statistical significance reached only increased 
mRNA level of DNaseI in spleen in Group 2 mice. IHC analysis of DNaseI on liver sections 
reflects results of DNaseI mRNA levels (Figure 2E lower panels). Quantification of staining 
intensity of DNaseI on kidney and liver sections of BW mice is provided in Supplementary 
Figure 1A, C, and demonstrates loss of DNase I in kidneys, but not in livers.   
Data in Figure 2D demonstrate no reduction of serum DNaseI enzyme activity, as 
determined in Group 3 compared with Group 1 and Group 2 mice. Interestingly, zymograms 
of serum samples exhibit a pattern similar to that seen in zymograms of liver lysates, in 
agreement with a report showing that liver is a main source of serum DNaseI.16    
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The mRNA level and enzyme activity of renal DNaseI in age and sex-matched 
BALB/c mice are presented in Supplementary Figure 2A. As demonstrated, DNaseI is 
expressed at stable levels in all groups of the control animals. Delta Ct values and calculated 
folds change of renal DNaseI mRNA levels in examined groups of BW and BALB/c mice are 
shown in Supplementary Table 1.  
    
Total nuclease activity in kidneys, livers, spleens and sera of BW mice.  
Results of the DNaseI zymography lead us to analyze if DNaseI levels influenced on total 
nuclease activity in kidneys, livers, spleens and sera of BW mice during progression of lupus 
nephritis. Figure 3 demonstrates nuclease activity, as determine by a single radial diffusion 
nuclease assay, in kidneys (A), livers (B), spleens (C) and sera (D) at different stages of the 
disease. Calculated group averages (+SD) are given as insert in each panel. The results 
demonstrate that there is  no decrease in total nuclease activity between Group 1, 2 or 3  in 
livers or spleens of BW mice, while total nuclease activity in kidneys of animals with sever 
nephritis (Group 3) is markedly reduced in comparison with mice in Group 1 and Group 2. In 
serum samples (Figure 3D), total nuclease activity was not reduced during lupus nephritis 
progression, similar to the results of DNaseI zymography on serum samples shown in Figure 
2D.  
 
Expression profiles of other nucleases in kidneys, livers and spleens from Group 1-3 BW 
mice. 
We measured gene expression levels of other endonucleases by real time PCR applied to 
kidneys, livers and spleens to analyze for two possible phenomena: i. selectivity of DNaseI 
down-regulation compared to the other nucleases, and ii. possible compensatory changes of 
other nucleases in all three organs in situations were the important renal DNaseI gene is shut 
 12
down. Figure 4 demonstrates mRNA levels of DNaseIl1, DNaseIl2, DNaseIl3, CAD, Dnase2a 
and EndoG in kidneys (A), livers (B) and spleens (C) of Group 1-3 BW mice. The average of 
each nuclease mRNA level in each group of mice is presented for each organ. There is no 
significant difference found in the transcriptional levels of any of the nucleases in kidneys, 
livers or spleens, except for those indicated by asterx in Figure 4B and 4C, when compared 
with the pre-nephritic (Group 1) mice. IHC analysis performed on kidney (Figure 5A) and 
liver (Figure 5B) sections confirmed the results of real time PCR on CAD (Figure 5 A, B 
upper panels) and EndoG (Figure 5A, B low panels), as the staining intensity was consistently 
similar in all groups of mice. Quantitative scoring analysis of staining intensity of CAD and 
EndoG on kidney and liver sections is provided in Supplementary Figure 1A, B, and showed 
stable expression throughout the observation period. Expression profiles of renal DNaseIl1, 
DNaseIl2, DNaseIl3, CAD, Dnase2a and EndoG in age and sex-matched BALB/c mice 
demonstrated in Supplementary Figure 2B, and showed largely stable values for all 
endonucleases studied throughout the observation period.   
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Discussion 
The role of reduced DNaseI in the pathogenesis of SLE has been discussed for decades. 
DNaseI was seen as a promising target for substitutive therapy to prevent autoimmunity26 but 
was fallen into oblivion for years after insufficient results of the trial treatment.27 In one single 
reported study done by Macanovic et al., injection of DNaseI in pre-nephritic BW mice 
postponed the disease, while treating nephritic animals decreased level of proteinuria and 
serum creatinin.26 Unfortunately, these observations were not followed by further penetrating 
studies that would provide insight into the therapeutic effect of DNaseI treatment. In another 
study performed in 1998, administration of DNaseI in BW mice did not affect development or 
progression of lupus nephritis.28 Similarly, intravenous or subcutaneous administration of 
recombinant human DNaseI in patients with lupus nephritis class III-V did not show any 
impact on kidney function or activity of the disease.27 This may signify that serum DNaseI 
has little or no influence on degradation of chromatin in dying renal cells.29 Only intra-cellular 
renal DNaseI initiates and ensures a safe and effective degradation of chromatin in dying cells 
within the kidneys (see e.g.29).  
Tubular cells dominate among renal cells that express DNaseI (Figure 2E),9,15,30 but 
DNaseI is also expressed in mesangial cells (15, unpublished data). Detection of apoptotic 
cells in kidney sections demonstrated that both tubular and glomerular cells undergo 
apoptosis.10,11,21 Reduced DNaseI expression is furthermore observed uniformly in glomerular 
and tubular cells in BW mice with severe nephritis.15 An acquired loss of renal DNaseI in 
lupus nephritis may therefore be the event that results in reduced chromatin fragmentation in a 
dominant proportion of renal cells, resulting in exposure of large chromatin fragments within 
the kidneys. Such fragments participate in the formation of immune complexes in GBM and 
thus accounts for progression of lupus nephritis into end-stage organ disease.  
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 To better understand the role of DNaseI expression in progressive lupus nephritis, it 
became important to determine 3 aspects of this phenomenon: i. is shut-down of renal DNaseI 
unique for DNaseI, or do other renal nucleases behave in a similar manner; ii. is renal DNaseI 
shut-down unique to kidneys, or is DNaseI down-regulated in other organs as well; and iii. are 
other nucleases up-regulated as a compensation in situations where DNaseI is lost in the 
kidneys.  
Data in the present study provide answers to all these aspects. For the first, data 
confirm that renal DNaseI is lost when lupus nephritis transform mild into severe membrano-
proliferative organ disease.8,15  Among expression profiles of 7 nucleases analyzed in kidneys, 
livers and spleens, reduced nuclease expression is restricted to DNaseI, in agreement with a 
recent preliminary observation.15 Furthermore, the DNaseI shut-down was restricted to the 
kidneys of BW mice with severe nephritis, as expression appeared normal in livers and 
spleens of the same animals. Importantly, no clear tendency for compensatory up-regulation 
of other nucleases involved in the initial fragmentation (DNaseI and CAD) or in subsequent 
chromatin degradation (EndoG, Dnase2) was observed.29,31     
Notably, serum DNaseI activity in the different groups of mice correlated with DNaseI 
activity in the liver and not in the kidney, in accordance with results provided by Ludwig et 
al.16 There are several reports about reduced serum DNaseI activity in patients with SLE 32-35 
and lupus-prone mice.14,15 All of those analyses are based on measurement of nuclease 
activity in sera by radial diffusion assay which is a sensitive but not a DNaseI specific 
method. Published data indicating correlation of serum DNaseI activity with activity of SLE 
or with renal involvement in SLE remain, however, controversial. The first study done by 
Chitrabamrung on 36 SLE patients demonstrated that individuals with active lupus (including 
active lupus nephritis) had the lowest level of enzymatic activity compared with healthy 
volunteers, patients with rheumatoid arthritis and scleroderma.32 This observation was 
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challenged by Sallai et al,34 who demonstrated  that serum DNaseI did not correlate with 
disease activity among 113 SLE patients with or without lupus nephritis. Moreover, activity 
of serum DNaseI in SLE patients was not reduced compared to enzymatic activity in patients 
with undifferentiated connective tissue disease.34 Data in our study demonstrate that total 
serum nuclease activity, as well as selective serum DNaseI activity were not reduced in BW 
mice during progression of lupus nephritis. Thus, serum DNaseI may not be important for the 
kidneys in a situation were renal DNaseI is lost. This may also explain why injection of 
DNaseI does not affect the activity of lupus nephritis in patients..27 This leaves us with the 
perception that renal, intra-cellular DNaseI is required for safe degradation and elimination of 
chromatin from dying renal cells. Without this enzyme, chromatin degradation is impaired, 
and large chromatin fragments accumulate in situ, where they are released from dying cells. 
This may indeed be one of the factors that result in impaired clearance of apoptotic, secondary 
necrotic cell debris.36-39  
Interestingly, we found increased DNaseI mRNA level and enzyme activity in liver 
and in spleen in early and late stages of nephritis. The observed increase of DNaseI 
expression in those organs was associated with high titers of serum anti-dsDNA antibodies. 
Since one common function of liver and spleen is uptake of circulating immune complexes 
we assume that DNaseI may participate in chromatin degradation of cleared IC. This may 
eventually explain increased DNaseI expression in these organs.  
 Selective loss of renal DNaseI creates a basis for in situ deposition of chromatin, a 
phenomenon independently demonstrated in different experimental nuclease deficiencies. In 
several of such studies, it is demonstrated that chromatin fragments accumulates in situ where 
it is released from dead cells (reviewed in40) instead of entering circulation, which would 
eventually promote deposition in distant organs as well.  
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The present results add weight to the assumption that DNaseI shut-down is secondary 
to early anti-dsDNA antibody-mediated deposition of immune complexes in the mesangial 
matrix.8 This may mean that inflammation linked to (silent or mild) mesangial nephritis in 
fact impose the loss of renal DNaseI with the consequences for renal function as described 
here. This proposed mechanism is in agreement with results of high resolution techniques to 
determine the nature of target structures within the glomeruli. These structures appear as 
electron-dense structures (EDS) by transmission electron microscopy (TEM), and have been 
shown to be composed of chromatin fragments and IgG molecules by different forms of 
immune electron microscopy and by co-localization terminal deoxy-nucleotidyl-transferase 
(TdT) biotin-dUTP nicked end-labeled (TUNEL) IEM assay.41-43  
Comparative studies of components and localization of EDS in skin and glomeruli in 
SLE demonstrated that they are composed of similar chromatin-related structures.41,42 
Deposition of ICs in glomeruli did not, however, predict deposition in skin.41,42 Examination 
of DNaseI expression in skin of MRL-lpr/lpr and BW mice has demonstrated stable DNaseI 
activity during development of lupus nephritis.42 Those results indicate that chromatin-IgG 
complexes that deposits in skin have another origin than from skin itself. In harmony with this 
published data demonstrate presence of polyomovirus large T antigen in extra-cellular 
chromatin associated with glomerular and skin membranes,41 suggesting that chromatin 
fragments in both kidneys and skin might derive from polyomovirus-infected renal cells since 
renal polyomovirus infection is a frequent finding in patients with lupus nephritis.22 Further 
investigations are needed to confirm if chromatin fragments found in skin EDS of SLE 
patients have a renal origin. 
 The precise mechanism by which renal DNaseI is shutting down is unknown, but is 
currently analyzed in our laboratory. Contemporarily, we follow three lines of analyses: 
transcriptional interference with a convergently encoded gene (Trap1) which overlaps with 
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the DNaseI gene in their 3’ untranslated region; regulation by microRNAs; or by DNA 
methylation. The initial event, accounting for DNaseI shut-down may, however, represent a 
response to inflammatory signals provided by the early mesangial nephritis. This would be in 
favor of transcriptional interference with the Trap1 gene, since Trap1 is upregulated during 
stress and inflammation (43,44, manuscript in preparation). Therefore, we currently perform in-
vitro studies using cultures of primary mesangial and tubular cells exposed to autoantibodies, 
nucleosomes, immune complexes and pro-inflammatory cytokines to determine impact of the 
inflammatory mesangial nephritis environment on DNaseI expression in renal cells. We also 
analyze the impact of albumin overload on ability of tubular cells to express DNaseI since its 
contribution to renal proximal cell apoptosis has been reported.45,46 Furthermore, microRNA 
targeting DNaseI mRNA has been identified in the mesangial nephritis and in end-stage organ 
disease in our laboratory (studies in progress).   
 From data presented here, adding to previous results,8,10,11,15 we may conclude that the 
processer accounting for transformation of mild mesangial nephritis into severe end-stage 
organ disease is linked to events within the kidneys, and is selective for the kidneys. This 
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1 12 0 - - - - 
2 12 0 - - - - 
1 
3 12 0 - - - - 
        
4 30 100 1+ + - - 
5 30 1400 - + - - 
2 
6 30 3000 - + - - 
        
7 32 800 4+ + + - 
8 26 200 4+ + + - 
9 32 200 4+ + + - 
10 27 500 4+ + + - 
11 24 400 4+ + + - 
3 
12 24 400 4+ + + - 
 
*   Proteinuria was determined by urine stix: 0–1+ (≤0.3 g/L, regarded as physiological 
proteinuria); 2+, (> 1 g/L); 3+, (> 3 g/L); and 4+, (≥ 20 g/L). 




Figure 1. Immune electron microscopy analyses of electron-dense structures (EDS) in 
kidneys and livers from BW mice at different stages of lupus nephritis. BW mice were 
divided into 3 groups according to kidney morphology (upper panels): Group 1 – mice 
without EDS in glomeruli; Group 2 – animals with immune deposits in mesangium; Group 3 
– mice with deposition in both mesangial matrix and glomerular basement membranes. In-
vivo bound IgG are traced by 5 nm gold particles. No EDS was, however, found in arterial or 
capillary walls in corresponding liver sections in Group 1-3 BW mice (lower panels).       
 
Figure 2. DNaseI expression in organs and sera of BW mice at different stages of lupus 
nephritis.  The mRNA levels (columns) and enzyme activity (gels) of DNaseI are determined 
in kidneys (A), livers (B) and spleens (D) of individual BW mice in pre-nephritic Group 1 
mice, and in mice with mesangial nephritis (Group 2) or with membrane-proliferative 
nephritis (Group 3). Insert in each panel demonstrates mean (+ SD) of DNaseI mRNA levels 
in each group for each organ. Asterix indicates a significant difference compared to Group 1 
(p<0.05). The mRNA levels of DNaseI in livers and spleens of BW mice with sever nephritis 
(Group 3) is not reduced while it is dramatically low in kidneys of the same animals. Enzyme 
activity of DNaseI measured by SDS-PAGE zymography for kidneys and livers, and by 
Native PAGE zymography for spleen samples correlates well with results of mRNA levels. 
DNaseI activity in sera of individual BW mice (D) in the different groups of lupus nephritis, 
as measured by SDS-PAGE zymography, is similar to the expression patterns of the DNaseI 
activity in livers and is not reduced in Group 3 BW mice. IHC analysis of DNaseI expression 
in kidney (E upper panels) and liver (E lower panels) sections in Group 2 and 3 BW mice is 
demonstrated in comparison to expression in age-matched healthy controls. Expression of 
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DNaseI in tubular cells of BW mice with sever nephritis (Group 3) is nearby undetectable 
while it is normally present in liver sections in the same animals. Magnification x 200. 
 
Figure 3.  Total nuclease activity in organs and sera of BW mice at different stages of 
lupus nephritis. Nuclease activity in kidney (A), liver (B), spleen (C) and serum samples (D) 
of individual BW mice is measured by a single radial nuclease diffusion assay. Insert in each 
panel represents mean (+ SD) of total nuclease activity in each group for each organ. The 
asterix indicates a significant difference compared to Group 1 (p<0.05). Only in kidneys 
nuclease activity is markedly reduced in Group 3 BW mice.  
 
Figure 4. Expression profiles of DNaseIl1-3, caspase-activated Dnase, Dnase2a and 
endonuclease G in BW mice during progression of lupus nephritis. The mRNA levels of 
different nucleases are determined in kidneys (A), livers (B) and spleens (C) in pre-nephritic 
Group 1 mice, in mice with mesangial nephritis (Group 2) and in mice with membrano-
proliferative lupus nephritis (Group 3). Values are given as mean (+ SD). Asterix indicates a 
significant difference compared to Group 1 (p<0.05). No significant changes in transcription 
levels of DNaseIl1-3, CAD, Dnase2a and EndoG was observed in kidneys in BW mice at 
different stages of lupus nephritis.  
 
Figure 5. IHC analysis of caspase-activated Dnase (CAD) and endonuclease G (endoG) 
in kidneys and livers from BW mice. Expression of CAD (A,B upper panels) and EndoG 
(A,B lower panels) proteins was determined in kidney (A) and liver (B) sections of BW mice 
in Group 2 and 3 and compared with data obtained in healthy BALB/C control mice. No 
difference in nuclease expression was observed in organs of BW mice with severe nephritis 









Figure 1. Immune electron microscopy analyses of electron-dense structures (EDS) in 
kidneys and livers from BW mice at different stages of lupus nephritis. 
BW mice were divided into 3 groups according to kidney morphology (upper panels): Group 1 
– mice without EDS in glomeruli; Group 2 – animals with immune deposits in mesangium; 
Group 3 – mice with deposition in both mesangial matrix and glomerular basement 
membranes. In-vivo bound IgG are traced by 5 nm gold particles. No EDS was, however, found 










































































































Healthy control Group2 Group3E.Figure 2. DNaseI expression in organs and sera of BW mice at different stages of lupus nephritis. The mRNA levels (columns) and enzyme 
activity (gels) of DNaseI are determined in kidneys (A), livers (B) and 
spleens (D) of individual BW mice in pre-nephritic Group 1 mice, and in 
mice with mesangial nephritis (Group 2) or with membrane-proliferative 
nephritis (Group 3). Insert in each panel demonstrates mean (+ SD) of 
DNaseI mRNA levels in each group for each organ. Asterix indicates a 
significant difference compared to Group 1 (p<0.05). The mRNA levels of 
DNaseI in livers and spleens of BW mice with sever nephritis (Group 3) is 
not reduced while it is dramatically low in kidneys of the same animals. 
Enzyme activity of DNaseI measured by SDS-PAGE zymography for 
kidneys and livers, and by Native PAGE zymography for spleen samples 
correlates well with results of mRNA levels. DNaseI activity in sera of
Individual BW mice (D) in the different groups of lupus nephritis, as measured by SDS-PAGE zymography, is similar to the expression patterns of 
the DNaseI activity in livers and is not reduced in Group 3 BW mice. IHC analysis of DNaseI expression in kidney (E upper panels) and liver (E 
lower panels) sections in Group 2 and 3 BW mice is demonstrated in comparison to expression in age-matched healthy controls. Expression of 
DNaseI in tubular cells of BW mice with sever nephritis (Group 3) is nearby undetectable while it is normally present in liver sections in the same 
























































































Figure 3.  Total nuclease activity in organs and sera of BW mice at 
different stages of lupus nephritis. Nuclease activity in kidney (A), liver (B), 
spleen (C) and serum samples (D) of individual BW mice is measured by a 
single radial nuclease diffusion assay. Insert in each panel represents mean (+ 
SD) of total nuclease activity in each group for each organ. The asterix 
indicates a significant difference compared to Group 1 (p<0.05). Only in 


















































Figure 4. Expression profiles of DNaseIl1-3, caspase-activated Dnase, Dnase2a and endonuclease G 
in BW mice during progression of lupus nephritis. The mRNA levels of different nucleases are 
determined in kidneys (A), livers (B) and spleens (C) in pre-nephritic Group 1 mice, in mice with 
mesangial nephritis (Group 2) and in mice with membrano-proliferative lupus nephritis (Group 3). Values 
are given as mean (+ SD). Asterix indicates a significant difference compared to Group 1 (p<0.05). No 
significant changes in transcription levels of DNaseIl1-3, CAD, Dnase2a and EndoG was observed in 
kidneys in BW mice at different stages of lupus nephritis. 















Healthy control Group 2 Group 3
Figure 5. IHC analysis of caspase-activated Dnase (CAD) and 
endonuclease G (endoG) in kidneys and livers from BW mice. 
Expression of CAD (A,B upper panels) and EndoG (A,B lower panels) 
proteins was determined in kidney (A) and liver (B) sections of BW mice 
in Group 2 and 3 and compared with data obtained in healthy BALB/C 
control mice. No difference in nuclease expression was observed in organs 
of BW mice with severe nephritis when compared with data from control 







































































Figure 1S. Quantitative analysis of DNaseI, CAD and EndoG expressions on kidney and liver sections of nephritic BW 
mice. Intensity of cells staining on kidney (A) and liver (B) sections with anti-DNaseI, CAD and EndoG antibodies were 
quantified  by immunoexpression score (IEXP-SC) = AEX x ISI, where AEX = percentage cellular area of expression and ISI = 
immunostaining intensity. Given numbers are the averages of  IEXP-SC in 10 view fields (±SD). Where is 0 represent negative- 
IEXP-SC; 1-100 is weakly positive-IEXP-SC; 101-200 is moderately positive-IEXP-SC and 201-300 is strongly positive-IEXP- 
SC. Expression of DNaseI is markedly reduced in Group 3 of BW mouse with membrano-proliferative nephritis while it is 
strongly expressed in healthy control and BW mouse with mild mesangial nephritis in Group 2 (A). No significant differences 
were observed in nucleases expression in livers between healthy control and BW mice in Group 2 and 3 (B). The percentage of 
tubular cells with expression of DNaseI quantified by IEXP-SC as strongly positive and tubular cells with totally absent DNaseI 
expression quantified by IEXP-SC as negative were determined on kidney sections from healthy control and BW mice Group 2 
and 3 (C). Renal cells that did not express DNaseI were present only on kidney section from BW mouse with severe nephritis 
Group3. Amount of cells that had DNaseI expression equivalent to that observed on section from healthy control was dramatically 
reduced on kidney section of BW mouse Group 3. Asterix indicates a significant difference compared to Healthy control and 


















































Figure 2S. Expression profiles of nucleases in kidneys of BALB/c mice. The mRNA levels 
(columns) and enzyme activity (gels) of DNaseI are determined in kidneys of female BALB/c 
mice divided into three groups accordingly to age of BW mice in Group 1-3 (A). Insert in panel 
demonstrates mean (±SD) of renal DNaseI mRNA levels. Expression and enzyme activity of 
DNaseI is stable in kidneys of BALB/c mice at different age groups. The mRNA levels of 
DNaseIl1-3, CAD, Dnase2a and EndoG are not significantly different in kidneys of BALB/c 
mice in Group 2 and 3 compared to transcription levels in Group 1 (B). Values are given as 
mean (±SD).




 Group 1 Group 2  
 
Group 3 
 Delta Ct values 
 
BW 0.86±0.16 0.99±0.19 3.43±1.49† 
BALB/c 1,79±0.1 2,27±0.42 2,10±0.45 
 Fold change 
 
Normalization to Group1 BW    
BW  1.00±0.11 0.90±0.13 0.20±0.13‡,§ 
BALB/c 0.67±0.04‡ 0.49±0.13‡ 0.54±0.10‡ 
Normalization to Group1 BALB/c    
BALB/c  1.00±0.07 0.73±0.20 0.81±0.14‡ 
BW 1.90±0.20§ 1.75±0.24§ 0.43±0.25‡,§ 
 
* Data are given as mean ± SD 
† Means statistically significant P < 0.007 in delta Ct values versus Group1 BW mice    
‡ Means statistically significant at P < 0.05 in fold change versus Group1 BW mice 
§ Means statistically significant at P < 0.05 in fold change versus Group1 BALB/c mice 
            
